FDA probing pancreatitis, pre-cancerous findings with GLP-1s, DPP-4s
This article was originally published in Scrip
Executive Summary
Although the details of academic research under examination by the FDA have yet to be published, the data were concerning enough for the agency to warn patients and prescribers about the potential for an increased risk of pancreatitis and pancreatic duct metaplasia, or pre-cancerous cellular changes, in patients with Type II diabetes treated with incretin mimetics, like Amylin's glucagon-like peptide-1 (GLP-1) receptor agonists Byetta (exenatide) and Bydureon (exenatide extended-release) and Merck's dipeptidyl peptidase-4 (DPP-4) inhibitors Januvia (sitagliptin), Janumet (sitagliptin/metformin) and Juvisync (sitagliptin/simvastatin).